Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Fig. 2

Changes in vocal function and surgery-free interval in patients with recurrent respiratory papillomatosis. a, A spider plot of change in VHI-10 scores is shown. b, A swimmer’s plot that demonstrates the frequency of surgical interventions before and after treatment with avelumab is shown. Each patient received a protocol indicated surgical intervention that occurred 6 or 12 weeks after initiation of avelumab at time zero. Yellow regions indicate the administration of a systemic therapy (anti-PD-1 mAb for patient 2, systemic bevacizumab for patients 3 and 4) for some patients after completing the protocol. c, The change in the number of clinically indicated surgical interventions per 12 patient-months before and after completion of the study. P = 0.008 by Wilcoxon matched-pairs analysis

Back to article page